

PRESS RELEASE



EMOBOT and GHU Paris Psychiatrie & Neurosciences Announce Research Partnership for the COGPSY Study to Better Understand Cognitive and Emotional Alterations in Neuropsychiatric Disorders, Particularly in Patients Treated with Esketamine

Paris, March 11, 2026 – **EMOBOT**, a startup specializing in artificial intelligence applied to mental health, and **GHU Paris Psychiatrie & Neurosciences**, the leading French and European hospital group dedicated to psychiatry and neurosciences, announce the signing of a strategic scientific partnership within the framework of the **COGPSY** study (Characterization of high-level cognitive alterations in patients suffering from neuropsychiatric disorders).

This collaboration aims to enrich the COGPSY study by integrating emotional and decisional digital biomarkers to better characterize the links between cognition, emotions, and severe neuropsychiatric disorders, particularly in patients receiving rapid-acting treatments such as esketamine (**Spravato®**).

A New Step for Translational Research in Psychiatry and Neurosciences

The COGPSY study, coordinated by **Pr. Fabien Vinckier** and Dr. Jacob Dhoté, aims to build a trans-nosographic atlas of high-level cognitive alterations observed across a wide spectrum of psychiatric and neurological disorders (depression, bipolar disorder, schizophrenia, neurodevelopmental disorders, neurodegenerative diseases, epilepsy, etc.) in comparison with healthy volunteers.

Within this framework, particular attention is paid to patients receiving rapid-acting treatments, notably esketamine (**Spravato®**), for whom detailed and longitudinal monitoring of emotional and cognitive dimensions represents a major clinical challenge. These treatments, which induce rapid effects on mood and symptomatology, constitute a privileged model for studying the dynamics of cognitive and emotional alterations.



From left to right in the photo: Pr. Fabien Vinckier (GHU Paris), Tanel Petelot (CEO Emobot), Marin Chapelle (GHU Paris)

Digital Biomarkers to Better Understand Cognitive and Emotional Mechanisms

The technology developed by EMOBOT is based on the analysis of multimodal signals (facial emotions, prosody, actigraphy, digital behavior), identifying computational markers of emotional, motivational, and decisional states.

Integrated into the COGPSY protocol, these biomarkers will notably allow:

- Exploring interactions between emotional fluctuations and cognitive performance.
- Studying implicit markers of decision-making.
- Longitudinally monitoring treatment response kinetics, particularly in patients receiving esketamine.

In patients treated with esketamine, these digital biomarkers will allow for the detailed and continuous exploration of emotional and cognitive response kinetics beyond periodic evaluations, identifying early markers of treatment response or non-response. This approach paves the way for a more refined and dynamic understanding of neuropsychiatric disorders beyond traditional clinical assessments.

GHU Paris: A Central Player in the COGPSY Project

GHU Paris Psychiatrie & Neurosciences, the sponsor of the COGPSY study, mobilizes its clinical, scientific, and methodological expertise to coordinate this large-scale research conducted across multiple centers, including patients and healthy volunteers over the long term.

"The integration of implicit and longitudinal emotional measurements into a large-scale cognitive study like COGPSY constitutes a unique opportunity. This partnership with EMOBOT allows us to explore, in an innovative way, the links between cognition, emotions, and decision-making in neuropsychiatric disorders," states **Professor Fabien Vinckier**, psychiatrist at GHU Paris and scientific lead of the study.

Close Collaboration Serving Scientific Innovation

This partnership relies on close cooperation between the teams at EMOBOT and GHU Paris:

- **EMOBOT** provides its digital medical device, expertise in artificial intelligence, signal processing, and data analysis.
- **GHU Paris** ensures the promotion of the study, participant inclusion, the conduct of clinical and cognitive evaluations, and the scientific validation of results.

"With COGPSY, we are taking a new step in using digital biomarkers to better understand the cognitive and emotional mechanisms at work in psychiatric and neurological disorders. This collaboration fully illustrates our ambition to put AI at the service of high-level clinical research," emphasizes **Tanel Petelot**, CEO and co-founder of EMOBOT.

Toward Better Characterization and Personalization of Care

Ultimately, the results from COGPSY and its ancillary study could contribute to:

- Better characterization of cognitive and emotional profiles.
- Identification of useful markers for longitudinal monitoring.
- Improvement of differential diagnosis strategies and personalization of care in psychiatry and neurology.

This work could prove particularly useful in the context of innovative rapid-acting therapies, contributing to a better understanding of their effects on cognition, decision-making, and emotions, and optimizing clinical follow-up for patients.

GHU Paris Psychiatrie & Neurosciences and EMOBOT thus reaffirm their common commitment to innovative, rigorous research at the service of patients.

Press Contacts:

 **EMOBOT** – Tanel Petelot, CEO & Co-founder – press@emobot.fr

 **GHU Paris Psychiatrie & Neurosciences** – Communications Department – communication@ghu-paris.fr